New pill for ulcerative colitis shows promise, but trial halted early

NCT ID NCT05785715

Terminated Disease control Sponsor: AbbVie Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested an oral medication, NX-13, in 81 adults with moderate to severe ulcerative colitis. Participants received either NX-13 or a placebo for 12 weeks, with a long-term follow-up option. The trial was terminated early, so the full results are not available, but the data may still help researchers understand if NX-13 can safely control disease activity.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: NX-13 (oral tablet)
What this could lead to: If successful, NX-13 could offer a new oral treatment option to help control moderate to severe ulcerative colitis.
What could go wrong: This early-phase trial was terminated, so results are limited. It is unclear if NX-13 is effective or safe; more research is needed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

follicular lymphoma ulcerative colitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ULCERATIVE COLITIS

Contacts and locations

Locations

AmiCare Centrum Medyczne

Jelenia Góra, Poland
AmiCare Sp. z o.o. Sp.k.

Lodz, Poland
Amicare Sp z o.o. S.K

Opoczno, Poland
Azienda Ospedaliera - Universitaria Sant' Andrea

Roma, Italy
Azienda Ospedaliera Ordine Mauriziano di Torino

Torino, Italy
Centrum Badań Klinicznych Piotr Napora Lekarze Sp. p.

Wroclaw, Poland
Centrum Diagnostyczno - Lecznicze Barska

Włocławek, Poland
ClinSante - Ośrodek Badań Klinicznych w Bydgoszczy

Bydgoszcz, Poland
Clinical Research Institute of Michigan

Troy, Michigan, 48098, United States
Digestive Disease Specialist, Inc-INTEGRIS Baptist Medical Center

Oklahoma City, Oklahoma, 73112, United States
Digestive Health Associates of Texas-GI Alliance

Mansfield, Texas, 76003, United States
Digestive Health Associates of Texas-GI Alliance Research-Garland

Garland, Texas, 75044, United States
Digestive Health Center of Michigan

Chesterfield, Michigan, 48047, United States
Endoskopia Sp. z o.o.

Sopot, Poland
GCP Clinical Research

Tampa, Florida, 33609, United States
H-T Centrum Medyczne

Tychy, Poland
IRCCS Fondazione Casa Sollievo della Sofferenza SG Rotondo

San Giovanni Rotondo, Italy
Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) - Istituto Clinico Humanitas

Rozzano, Italy
Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) - Ospedale San Raffaele

Milan, Italy
Krakowska Przychodnia FutureMeds

Krakow, Poland
Medical College of Wisconsin

Milwaukee, Wisconsin, 53226, United States
Miami Clinical Research

Miami, Florida, 33155, United States
Office of Jaroslaw Kierkus, Dr N Med

Warsaw, Poland
Orlando Health, Inc.

Orlando, Florida, 32806, United States
Przychodnia Vitamed NFZ

Bydgoszcz, Poland
RiverMED Poradnie Specjalistyczne Poznań

Poznan, Poland
Sonomed Sp. z o.o. Centrum Medyczne

Szczecin, Poland
Texas Digestive Disease Consultants-GI Alliance Research

Southlake, Texas, 76092, United States
Torunskiego Centrum Gastrologii I Endoskopii - Gastromed

Torun, Poland
Twoja Przychodnia Opolskie Centrum Medyczne

Opole, Poland
Twoja Przychodnia Szczecińskie Centrum Medyczne

Szczecin, Poland
Universitair Ziekenhuis Leuven - Campus Gasthuisberg

Leuven, Belgium
VITA LONGA Clinic - Katowice

Katowice, Poland
Washington University School of Medicine in St. Louis

St Louis, Missouri, 63110, United States
Zabobrze Centrum Medyczne

Wroclaw, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.